Abstract

Cationic amphiphilic peptides (CAPs) are usually classified as bacterial membrane targeting molecules. Rational design and modification of cationic and amphiphilic properties of CAPs have made them to be used in new medical and biotechnological applications. However, CAPs modification and development strategies are challenging issues due to the risk of cytotoxicity or hemolytic activity. In this research, modified variants of S3 peptide were introduced. S3 is a linear 34 amino acid peptide derived from the lipopolysaccharide (LPS) binding site of factor C in horseshoe crab’s hemolymph. Net positive charges of variants (S3E3 and S3E3A) increased by either eliminating negatively charged residues of the peptides or substituting them with alanine. Different biological activities of new variants including LPS binding affinity, antimicrobial activity, cytotoxicity against human breast tumor cell line, and hemolytic property were studied and compared to those of S3 peptide. S3E3 variant showed 68.5% higher LPS binding affinity, 40.4% stronger anti-microbial activity, conserved hemolytic property with the same anti-cancer activity compared to S3peptide. These results revealed that elimination/substitution of negatively charged residues will be a proper strategy for modification of S3 peptide.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call